You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This book presents the ‘state of the art’ of biomarkers research in neuropsychiatric conditions, from dementia to eating disorders, as well as providing methodological, practical and ethical issues related to the development of biomarkers. Biomarkers have revolutionized clinical research and practice in most fields of medicine, but psychiatry has lagged behind. However, in the last decade, there has been a growing expectation that biomarkers will advance and, ultimately, reframe psychiatry research and practice. Biomarkers might inform about diagnosis, therapeutics, prognosis, contributing to a ‘personalized medicine’. Understanding their meaning, possibilities and limitations will help clinicians, researchers and students in the related areas navigate and excel in the challenging and ever changing field of neuropsychiatric disorders.
Major psychiatric disorders, including schizophrenia, bipolar disorder and major depression represent complex phenotypes with imprecise diagnostic boundaries. It has been found that these disorders can be characterized by a number of peripheral immune-inflammatory alterations, including, i.e. elevated levels of pro-inflammatory cytokines, increased levels of specific and non-specific antibodies or abnormal counts of lymphocyte subpopulations. Although it has been found that major psychiatric disorders share similar dysregulations of immune-inflammatory response, recent studies have also clearly demonstrated that some differences can be indicated. Interestingly, certain immune-inflammatory di...
Using a transdiagnostic framework, this book describes how mental health professionals can diagnose and treat OCD and related disorder.
This book assembles and presents the available data on the immune/inflammatory dysfunction in psychiatric disorders, indicating the potential of immune mechanisms as either biomarkers or therapeutic targets, as well as discussing the challenges ahead of incorporating this knowledge into clinical practice.
Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progre...